(Q40581686)

21 September 2017

1 reference

title

Role of pharmacologic tests in the treatment of primary pulmonary hypertension (English)

1 reference

21 September 2017

N Galiè

1

1 reference

21 September 2017

G Ussia

2

1 reference

21 September 2017

P Passarelli

3

1 reference

21 September 2017

R Parlangeli

4

1 reference

21 September 2017

A Branzi

5

1 reference

21 September 2017

B Magnani

6

1 reference

21 September 2017

language of work or name

English

0 references

publication date

1 January 1995

1 reference

American Journal of Cardiology

21 September 2017

1 reference

21 September 2017

75

1 reference

21 September 2017

3

1 reference

21 September 2017

55A-62A

1 reference

Pulmonary hypertension with special reference to the vasoconstrictive factor

21 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980384-1

Primary pulmonary hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980384-1

Endothelial dysfunction in pulmonary hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980384-1

Primary pulmonary hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980384-1

Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980384-1

Primary pulmonary hypertension. Vascular structure, morphometry, and responsiveness to vasodilator agents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980384-1

The acute administration of vasodilators in primary pulmonary hypertension. Experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980384-1

Magnitude and implications of spontaneous hemodynamic variability in primary pulmonary hypertension.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980384-1

Vasodilators and pulmonary arterial hypertension: the paradox of therapeutic success and clinical failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980384-1

Pulmonary artery hemodynamics in primary pulmonary hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980384-1

DISTRIBUTION OF BLOOD FLOW IN ISOLATED LUNG; RELATION TO VASCULAR AND ALVEOLAR PRESSURES

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980384-1

On pulmonary vascular resistance: the need for more precise definition.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980384-1

Treatment of primary pulmonary hypertension with nifedipine. A hemodynamic and scintigraphic evaluation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980384-1

Pharmacologically induced pulmonary vasodilatation in children and young adults with primary pulmonary hypertension.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980384-1

Treatment of primary pulmonary hypertension intravenous epoprostenol (prostacyclin)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980384-1

Prostacyclin and acetylcholine as screening agents for acute pulmonary vasodilator responsiveness in primary pulmonary hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980384-1

The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980384-1

Survival in primary pulmonary hypertension. Validation of a prognostic equation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980384-1

Arachidonic Acid Metabolites and the Interactions between Platelets and Blood-Vessel Walls

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980384-1

Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980384-1

Pulmonary vasodilation with prostacyclin in primary and secondary pulmonary hypertension.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980384-1

Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980384-1

The management of primary pulmonary hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980384-1

Effect of acetylcholine on pulmonary vascular resistance in a patient with idiopathic pulmonary hypertension.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980384-1

Adenosine as a vasodilator in primary pulmonary hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980384-1

Comparison of the effects of adenosine and nifedipine in pulmonary hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980384-1

Effects of adenosine in combination with calcium channel blockers in patients with primary pulmonary hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980384-1

Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980384-1

Inhaled nitric oxide for the adult respiratory distress syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980384-1

Short-term effectiveness of nifedipine in secondary pulmonary hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980384-1

High dose titration of calcium channel blocking agents for primary pulmonary hypertension: guidelines for short-term drug testing.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980384-1

Prediction of favourable responses to long term vasodilator treatment of pulmonary hypertension by short term administration of epoprostenol (prostacyclin) or nifedipine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980384-1

Vasodilators and primary pulmonary hypertension. Variability of long-term response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980384-1

The effect of vasodilator therapy on the clinical outcome of patients with primary pulmonary hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980384-1

Profile of paediatric patients with pulmonary hypertension judged by responsiveness to vasodilators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980384-1

Is it ethical to administer vasodilator drugs to patients with primary pulmonary hypertension?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980384-1

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9149(99)80384-1

1 reference

21 September 2017

1 reference